CDK4 and breast carcinoma: Furthermore, CCNE1 expression has been suggested to be a predictive biomarker, with high CCNE1 RNA expression correlating with decreased progression-free survival in patients with metastatic hormone receptor–positive, HER2-negative breast cancer receiving the CDK4/6 inhibitor Palbociclib (39).